GUANGZHOU, China, Dec. 31, 2024 — Burning Rock Biotech Limited (NASDAQ: BNR), a precision oncology company utilizing next-generation sequencing (NGS) technology, reports that all shareholder resolutions were approved at its 2024 annual general meeting. These resolutions included:

1. Ratification of Ernst & Young Hua Ming LLP as the company’s auditor for the fiscal year ending December 31, 2024, and authorization for the directors to determine the auditor’s compensation;
2. Re-election of Yusheng Han and Gang Lu as directors; and
3. Authorization for the directors to take any necessary actions to implement the aforementioned resolutions.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), committed to safeguarding life through science, specializes in applying NGS technology to precision oncology. Its operations encompass NGS-based therapy selection testing for advanced-stage cancer patients and cancer early detection, currently progressing from research and development to clinical validation.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Contact: IR@brbiotech.com